Paper36969208
B cell targeted therapies in inflammatory autoimmune disease of the central nervous system.
Furman MJ and 7 others. Front Immunol, 2023. Cited by 27 papers, by iCite.
Cite this record
ConductScience Library. B cell targeted therapies in inflammatory autoimmune disease of the central nervous system. Papers, record 36969208. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36969208
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- B cell targeted therapies in inflammatory autoimmune disease of the central nervous system.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Autoimmune Diseases | Major topic |
| Multiple Sclerosis | Major topic |
| Humans | |
| Autoantibodies | |
| Central Nervous System | |
| B-Lymphocytes |
Source PubMed
References127
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28893994 | Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. | Proc Natl Acad Sci U S A | 2017 | https://conductscience.org/library/papers/28893994 | PubMed |
| 2 | 35882229 | Microglia in multiple sclerosis: Protectors turn destroyers. | Neuron | 2022 | https://conductscience.org/library/papers/35882229 | PubMed |
| 3 | 33406479 | Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1. | Neurol Neuroimmunol Neuroinflamm | 2021 | https://conductscience.org/library/papers/33406479 | PubMed |
| 4 | 30612739 | Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10. | Cell | 2019 | https://conductscience.org/library/papers/30612739 | PubMed |
| 5 | 33282676 | Bruton's Tyrosine Kinase Inhibition Promotes Myelin Repair. | Brain Plast | 2020 | https://conductscience.org/library/papers/33282676 | PubMed |
| 6 | 23684423 | The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. | Cytokine Growth Factor Rev | 2013 | https://conductscience.org/library/papers/23684423 | PubMed |
| 7 | 35970870 | Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex concept. | Nat Rev Neurol | 2022 | https://conductscience.org/library/papers/35970870 | PubMed |
| 8 | 29143550 | Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. | Mult Scler | 2019 | https://conductscience.org/library/papers/29143550 | PubMed |
| 9 | 26065586 | Antibody-independent functions of B cells: a focus on cytokines. | Nat Rev Immunol | 2015 | https://conductscience.org/library/papers/26065586 | PubMed |
| 10 | 34253922 | Single-cell profiling of CNS border compartment leukocytes reveals that B cells and their progenitors reside in non-diseased meninges. | Nat Neurosci | 2021 | https://conductscience.org/library/papers/34253922 | PubMed |
| 11 | 18383069 | Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. | Ann Neurol | 2008 | https://conductscience.org/library/papers/18383069 | PubMed |
| 12 | 34595983 | Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial. | Mult Scler | 2022 | https://conductscience.org/library/papers/34595983 | PubMed |
| 13 | 29593838 | B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. | Ther Adv Neurol Disord | 2018 | https://conductscience.org/library/papers/29593838 | PubMed |
| 14 | 29305608 | Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. | JAMA Neurol | 2018 | https://conductscience.org/library/papers/29305608 | PubMed |
| 15 | 26250739 | Immunopathology of multiple sclerosis. | Nat Rev Immunol | 2015 | https://conductscience.org/library/papers/26250739 | PubMed |
| 16 | 30988116 | Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models. | J Immunol | 2019 | https://conductscience.org/library/papers/30988116 | PubMed |
| 17 | 34745138 | Semi-Automated Live Tracking of Microglial Activation in CX3CR1GFP Mice During Experimental Autoimmune Encephalomyelitis by Confocal Scanning Laser Ophthalmoscopy. | Front Immunol | 2021 | https://conductscience.org/library/papers/34745138 | PubMed |
| 18 | 31617269 | Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis. | Eur J Neurol | 2020 | https://conductscience.org/library/papers/31617269 | PubMed |
| 19 | 33649164 | CNS Autoimmune Responses in BCMA-Deficient Mice Provide Insight for the Failure of Atacicept in MS. | Neurol Neuroimmunol Neuroinflamm | 2021 | https://conductscience.org/library/papers/33649164 | PubMed |
| 20 | 36001711 | Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. | N Engl J Med | 2022 | https://conductscience.org/library/papers/36001711 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42921194 | B-Cell-Related Neuroinflammation Across Central Nervous System Diseases: A Bibliometric and Science-Mapping Analysis, 2006-2026. | J Inflamm Res | 2026 | https://conductscience.org/library/papers/42921194 | PubMed |
| 42682178 | Physiologically Based Pharmacokinetic Modeling to Predict Human Starting Dose and Pharmacokinetics for Rocbrutinib. | Clin Transl Sci | 2026 | https://conductscience.org/library/papers/42682178 | PubMed |
| 41789172 | Editorial: Reviews in: multiple sclerosis and neuroimmunology. | Front Neurol | 2026 | https://conductscience.org/library/papers/41789172 | PubMed |
| 41787239 | Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis. | Neurol Ther | 2026 | https://conductscience.org/library/papers/41787239 | PubMed |
| 41270166 | Antigen-specific B cell response regulation by IL-10-producing tolerogenic dendritic cells. | Sci Adv | 2025 | https://conductscience.org/library/papers/41270166 | PubMed |
| 40901465 | B cell depletion as a therapeutic strategy for neuromyelitis optica spectrum disorder: rationale, evidence, and challenges. | Front Immunol | 2025 | https://conductscience.org/library/papers/40901465 | PubMed |
| 40089493 | Thyroid function and multiple sclerosis: a two-sample mendelian randomization study and mediation analysis. | Sci Rep | 2025 | https://conductscience.org/library/papers/40089493 | PubMed |
| 39872531 | Inebilizumab treatment in a patient with co-occurring AQP4-IgG positive neuromyelitis optica spectrum disorder and myasthenia gravis: a case report and literature review. | Front Immunol | 2024 | https://conductscience.org/library/papers/39872531 | PubMed |
| 39840055 | Hematopoietic stem cell transplantation as rescue therapy for refractory autoimmune retinopathy: a case report. | Front Immunol | 2024 | https://conductscience.org/library/papers/39840055 | PubMed |
| 39814995 | Analysis of changes in the chemokine CXC ligand 13 in serum and cerebrospinal fluid of patients with neuromyelitis optica. | Sci Rep | 2025 | https://conductscience.org/library/papers/39814995 | PubMed |
| 39641859 | TWEAK and TNFɑ Pro-inflammatory Soluble Cytokines and their Specific Autoantibodies Secretion in Multiple Sclerosis Patients. | Inflammation | 2025 | https://conductscience.org/library/papers/39641859 | PubMed |
| 39524382 | The indications and safety of rituximab for the treatment of pediatric autoimmune diseases: a single-center retrospective study. | Transl Pediatr | 2024 | https://conductscience.org/library/papers/39524382 | PubMed |
| 38717637 | A new perspective on therapies involving B-cell depletion in autoimmune diseases. | Mol Biol Rep | 2024 | https://conductscience.org/library/papers/38717637 | PubMed |
| 38435981 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Current Therapeutic Approaches and Future Outlooks. | Immunotargets Ther | 2024 | https://conductscience.org/library/papers/38435981 | PubMed |
| 38270296 | Immunosuppressive therapy and COVID-19 infection in patients with NMOSD. | Immun Inflamm Dis | 2024 | https://conductscience.org/library/papers/38270296 | PubMed |
| 38138980 | Epstein-Barr Virus and Human Endogenous Retrovirus in Japanese Patients with Autoimmune Demyelinating Disorders. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38138980 | PubMed |
| 38129902 | Bruton's tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder. | J Neuroinflammation | 2023 | https://conductscience.org/library/papers/38129902 | PubMed |
| 37638037 | S1PR-1/5 modulator RP-101074 shows beneficial effects in a model of central nervous system degeneration. | Front Immunol | 2023 | https://conductscience.org/library/papers/37638037 | PubMed |
Genes30
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36969208
GET https://conductscience.org/api/papers/v1/36969208/references?page=2